Eli Lilly's new weight-loss pill, orforglipron, showed promising results in a late-stage trial. Patients with obesity and type 2 diabetes lost an average of 10.5% of their body weight. The pill met its goals, lowering blood sugar levels and paving the way for global approval. While some side effects like nausea and vomiting were reported, doctors see the oral option as a significant advancement, potentially increasing access to weight-loss treatment due to easier manufacturing and potentially lower cost compared to injectable alternatives. Eli Lilly plans to launch the pill globally next year.

Prepared by Olivia Bennett and reviewed by editorial team.